Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
31
PTCT Quote, Financials, Valuation and Earnings
Last price:
$45.41
Seasonality move
:
7.01%
Day range:
$44.95 - $46.15
52-week range:
$23.58 - $54.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.85x
P/B ratio:
--
Volume:
185.8K
Avg. volume:
820.6K
1-year change:
64.25%
Market cap:
$3.5B
Revenue:
$937.8M
EPS (TTM):
-$5.94
Analysts' Opinion
-
Consensus RatingPTC Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 3 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of --, PTC Therapeutics has an estimated upside of 29.47% from its current price of $45.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $45.35.
Fair Value
-
According to the consensus of 10 analysts, PTC Therapeutics has 29.47% upside to fair value with a price target of -- per share.
PTCT vs. S&P 500
-
Over the past 5 trading days, PTC Therapeutics has underperformed the S&P 500 by -6.31% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
PTC Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PTC Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter PTC Therapeutics reported revenues of $196.8M.
Earnings Growth
-
PTC Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter PTC Therapeutics reported earnings per share of -$1.39.
Enterprise value:
2.8B
EV / Invested capital:
-3.60x
Price / LTM sales:
3.85x
EV / EBIT:
--
EV / Revenue:
3.07x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-10.10x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$830.4M
Return On Assets:
-26.04%
Net Income Margin (TTM):
-50.32%
Return On Equity:
--
Return On Invested Capital:
-425.51%
Operating Margin:
-26.41%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $696.6M | $798.2M | $900.7M | $196.6M | $196.8M | |
| Gross Profit | $653.5M | $750.9M | $830.4M | $187.1M | $185.9M | |
| Operating Income | -$376.1M | -$513.2M | -$127.8M | -$116.7M | -$52M | |
| EBITDA | -$338.7M | -$424.6M | -$105.7M | -$76.4M | -$49.9M | |
| Diluted EPS | -$7.47 | -$8.65 | -$5.94 | -$1.76 | -$1.39 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2B | $1B | $517.3M | $540.4M | $1.3B | |
| Total Assets | $2.2B | $2B | $1.6B | $1.3B | $1.8B | |
| Current Liabilities | $253.8M | $465.3M | $420.1M | $492.1M | $610.7M | |
| Total Liabilities | $1.7B | $1.9B | $1.8B | $1.9B | $2.9B | |
| Total Equity | $511M | $104.9M | -$226.9M | -$670.8M | -$1.1B | |
| Total Debt | $303M | $431M | $282.7M | $573.2M | $285.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$259.5M | -$224.1M | -$178M | -$14.5M | -$77M | |
| Cash From Investing | $326M | -$49.9M | -$317.9M | -$29.6M | -$42.7M | |
| Cash From Financing | -$130.6M | $328.8M | $849.9M | $3.4M | -$17.6M | |
| Free Cash Flow | -$409M | -$343.2M | -$274.2M | -$43.7M | -$87.8M | |
PTCT
Sector
Market Cap
$3.5B
$46.1M
Price % of 52-Week High
83.73%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
64.25%
-30.52%
Beta (5-Year)
0.629
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$46.24
200-day SMA
Buy
Level
$35.59
Bollinger Bands (100)
Buy
Level
33.56 - 44.64
Chaikin Money Flow
Buy
Level
14.9M
20-day SMA
Sell
Level
$47.43
Relative Strength Index (RSI14)
Sell
Level
48.74
ADX Line
Buy
Level
7.64
Williams %R
Buy
Level
-85.8871
50-day SMA
Buy
Level
$43.68
MACD (12, 26)
Buy
Level
0.61
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
58.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.0663)
Sell
CA Score
(Annual)
Level (-5.462)
Buy
Beneish M-Score
(Annual)
Level (-3.8308)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (6.683)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Stock Forecast FAQ
In the current month, PTCT has received 6 Buy ratings 3 Hold ratings, and 1 Sell ratings. The PTCT average analyst price target in the past 3 months is --.
-
Where Will PTC Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that PTC Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About PTC Therapeutics?
Analysts are divided on their view about PTC Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PTC Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is PTC Therapeutics's Price Target?
The price target for PTC Therapeutics over the next 1-year time period is forecast to be -- according to 10 Wall Street analysts, 6 of them rate the stock a Buy, 1 rates the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is PTCT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PTC Therapeutics is a Buy. 6 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PTCT?
You can purchase shares of PTC Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PTC Therapeutics shares.
-
What Is The PTC Therapeutics Share Price Today?
PTC Therapeutics was last trading at $45.41 per share. This represents the most recent stock quote for PTC Therapeutics. Yesterday, PTC Therapeutics closed at $45.35 per share.
-
How To Buy PTC Therapeutics Stock Online?
In order to purchase PTC Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
